Radiopharm Theranostics (RADX) Equity Average (2025)
Radiopharm Theranostics (RADX) reported Equity Average of $227415.4 for Q2 2025.
Radiopharm Theranostics (RADX) Equity Average (2025) Analysis & Trends
Radiopharm Theranostics (RADX) has 1 years of Equity Average data on file, last reported at $227415.4 in Q2 2025.
- Equity Average for Q2 2025 came in at $227415.4, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $227415.4 (changed N/A YoY), and the FY2025 annual result was $35.1 million, down 3.71% from the prior year.
- Equity Average steadied at $227415.4 in Q2 2025 per RADX's latest filing.
- Over five years, Equity Average peaked at $227415.4 in Q2 2025 and troughed at $227415.4 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Radiopharm Theranostics | 5.82 Bn | 5.81 Bn | - | 227,415.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 227,415.38 |